Vivoryon Therapeutics N.V. Stock

Equities

VVY

NL00150002Q7

Biotechnology & Medical Research

Real-time Euronext Amsterdam 10:11:20 2024-04-30 am EDT 5-day change 1st Jan Change
0.658 EUR -12.62% Intraday chart for Vivoryon Therapeutics N.V. -8.61% -91.92%
Sales 2023 -3.62K -3.88K Sales 2024 * - Capitalization 19.63M 21.01M
Net income 2023 -28M -29.97M Net income 2024 * -18M -19.27M EV / Sales 2023 -53,497 x
Net cash position 2023 18.52M 19.83M Net cash position 2024 * 19.55M 20.93M EV / Sales 2024 * -
P/E ratio 2023
-7.27 x
P/E ratio 2024 *
-1.05 x
Employees 15
Yield 2023 *
-
Yield 2024 *
-
Free-Float 66.56%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Vivoryon Therapeutics N.V.

1 day-12.62%
1 week-8.61%
Current month+21.85%
1 month+25.57%
3 months-92.77%
6 months-91.43%
Current year-91.92%
More quotes
1 week
0.62
Extreme 0.621
1.00
1 month
0.41
Extreme 0.41
1.00
Current year
0.41
Extreme 0.41
9.93
1 year
0.41
Extreme 0.41
19.56
3 years
0.41
Extreme 0.41
23.25
5 years
0.41
Extreme 0.41
23.25
10 years
0.41
Extreme 0.41
27.73
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 11-12-31
Director of Finance/CFO - -
Director/Board Member 56 18-08-30
Members of the board TitleAgeSince
Chairman 74 06-12-31
Director/Board Member 54 06-12-31
Director of Finance/CFO - -
More insiders
Date Price Change Volume
24-04-30 0.658 -12.62% 725 730
24-04-29 0.753 -5.88% 425,381
24-04-26 0.8 -2.44% 344,230
24-04-25 0.82 -8.38% 1,589,391
24-04-24 0.895 +24.31% 3,324,608

Real-time Euronext Amsterdam, April 30, 2024 at 10:11 am EDT

More quotes
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease. At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.753 EUR
Average target price
41.57 EUR
Spread / Average Target
+5,420.14%
Consensus

Annual profits - Rate of surprise